Loganin Inhibits Angiotensin II–Induced Cardiac Hypertrophy Through the JAK2/STAT3 and NF-κB Signaling Pathways
| Autor: | Jiajia Xu, Yan-ling Li, Run-jing Li, Weiwei Wang, Gang Song, Gongye Zhang, Cui Yang, Zhengrong Huang, Zheng-hao Zhang, Min-wei Chen, Shi-xiao Liu |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Cardiac fibrosis cardiac fibrosis Inflammation RM1-950 angiotensin II Pharmacology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine medicine Pharmacology (medical) NF-kB loganin STAT3 Original Research biology Chemistry Loganin cardiac hypertrophy JAK2/STAT3 medicine.disease Angiotensin II IκBα 030104 developmental biology inflammation 030220 oncology & carcinogenesis cardiovascular system biology.protein Cytokine secretion Therapeutics. Pharmacology Signal transduction medicine.symptom |
| Zdroj: | Frontiers in Pharmacology, Vol 12 (2021) Frontiers in Pharmacology |
| ISSN: | 1663-9812 |
| DOI: | 10.3389/fphar.2021.678886 |
| Popis: | Loganin is an iridoid glycoside extracted from Cornus officinalis, which is a traditional oriental medicine, and many biological properties of loganin have been reported. Nevertheless, it is not clear whether loganin has therapeutic effect on cardiovascular diseases. Hence, the aim of the present study was to investigate the effect of loganin on Ang II–induced cardiac hypertrophy. In the present study, we reported for the first time that loganin inhibits Ang II–provoked cardiac hypertrophy and cardiac damages in H9C2 cells and in mice. Furthermore, loganin can achieve cardioprotective effects through attenuating cardiac fibrosis, decreasing pro-inflammatory cytokine secretion, and suppressing the phosphorylation of critical proteins such as JAK2, STAT3, p65, and IκBα. Besides, the outstanding findings of the present study were to prove that loganin has no significant toxicity or side effects on normal cells and organs. Based on these results, we conclude that loganin mitigates Ang II–induced cardiac hypertrophy at least partially through inhibiting the JAK2/STAT3 and NF-κB signaling pathways. Accordingly, the natural product, loganin, might be a novel effective agent for the treatment of cardiac hypertrophy and heart failure. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|